165 related articles for article (PubMed ID: 38397894)
1. Bone Turnover Markers, n-Terminal Propeptide of Type I Procollagen and Tartrate-Resistant Acid Phosphatase Type 5b, for Predicting Castration Resistance in Prostate Cancer.
Kano H; Izumi K; Nakagawa R; Toriumi R; Aoyama S; Kamijima T; Makino T; Naito R; Iwamoto H; Yaegashi H; Kawaguchi S; Shigehara K; Nohara T; Mizokami A
Biomedicines; 2024 Jan; 12(2):. PubMed ID: 38397894
[TBL] [Abstract][Full Text] [Related]
2. Number of contiguous vertebral cross-links in the spine indicates bone formation: a cross-sectional study.
Furukawa M; Shibata R; Okuyama K
BMC Musculoskelet Disord; 2023 Sep; 24(1):736. PubMed ID: 37715167
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and prognostic significance of tartrate-resistant acid phosphatase type 5b in newly diagnosed prostate cancer with bone metastasis: A real-world multi-institutional study.
Yamamichi G; Kato T; Yumiba S; Tomiyama E; Koh Y; Nakano K; Matsushita M; Hayashi Y; Ishizuya Y; Watabe T; Hatano K; Kawashima A; Ujike T; Ono Y; Takada T; Takada S; Imamura R; Nonomura N; Uemura M
Int J Urol; 2023 Jan; 30(1):70-76. PubMed ID: 36305578
[TBL] [Abstract][Full Text] [Related]
4. TRACP-5b/BAP Score After 3 Months of Treatment With Combined SERM/E2 Therapy Can Predict Changes in Lumbar Spine Bone Mineral Density After 1 Year of Treatment in Early Postmenopausal Osteopenia.
Ota I; Ota Y; Ota K; Eda H; Ohta H
JBMR Plus; 2022 Nov; 6(11):e10690. PubMed ID: 36398113
[TBL] [Abstract][Full Text] [Related]
5. Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption.
Sølling AS; Harsløf T; Jørgensen NR; Langdahl B
Osteoporos Int; 2023 Mar; 34(3):599-605. PubMed ID: 36543965
[TBL] [Abstract][Full Text] [Related]
6. Bone Turnover Markers as a New Predicting Factor for Nonunion After Spinal Fusion Surgery.
Inose H; Yamada T; Mulati M; Hirai T; Ushio S; Yoshii T; Kato T; Kawabata S; Okawa A
Spine (Phila Pa 1976); 2018 Jan; 43(1):E29-E34. PubMed ID: 27879570
[TBL] [Abstract][Full Text] [Related]
7. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
[TBL] [Abstract][Full Text] [Related]
8. Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis.
Wu YY; Janckila AJ; Ku CH; Yu CP; Yu JC; Lee SH; Liu HY; Yam LT; Chao TY
BMC Cancer; 2010 Apr; 10():158. PubMed ID: 20416078
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of serum tartrate‑resistant acid phosphatase‑5b for bone metastasis in patients with resectable breast cancer.
Shimoda M; Sato Y; Abe K; Masunaga N; Tsukabe M; Yoshinami T; Sota Y; Miyake T; Tanei T; Shimazu K
Oncol Lett; 2024 Jun; 27(6):250. PubMed ID: 38638841
[TBL] [Abstract][Full Text] [Related]
10. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density.
Halleen JM; Ylipahkala H; Alatalo SL; Janckila AJ; Heikkinen JE; Suominen H; Cheng S; Väänänen HK
Calcif Tissue Int; 2002 Jul; 71(1):20-5. PubMed ID: 12073156
[TBL] [Abstract][Full Text] [Related]
11. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
[TBL] [Abstract][Full Text] [Related]
12. Changes in bone turnover markers after discontinuing long-term glucocorticoid administration in children with idiopathic nephrotic syndrome: a multicenter retrospective observational study.
Ueda Y; Okamoto T; Sato Y; Hayashi A; Takahashi T; Suzuki R; Aoyagi H; Ueno M; Kobayashi N; Uetake K; Nakanishi M; Ariga T; Manabe A
Pediatr Nephrol; 2023 Oct; 38(10):3285-3296. PubMed ID: 37052692
[TBL] [Abstract][Full Text] [Related]
13. Exercise-induced hypercalcemia and vasopressin-mediated bone resorption.
Senda M; Hamano T; Fujii N; Ito T; Sakaguchi Y; Matsui I; Isaka Y; Moriyama T
Osteoporos Int; 2021 Dec; 32(12):2533-2541. PubMed ID: 34137899
[TBL] [Abstract][Full Text] [Related]
14. High Uric Acid (UA) Negatively Affects Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b) Immunoassay.
Wu ZQ; Zhang Y; Xie E; Song WJ; Yang RX; Yan CJ; Zhang BF; Xu HG
PLoS One; 2016; 11(1):e0147554. PubMed ID: 26800211
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.
Tang C; Liu Y; Qin H; Li X; Guo W; Li J; Wang W; Qu L; Hu H; Xu C; Zheng L; Huang Y; Liu B; Gao H; Halleen JM; Liu X
Clin Chim Acta; 2013 Nov; 426():102-7. PubMed ID: 24055775
[TBL] [Abstract][Full Text] [Related]
16. Bone Metabolism in the Healing Process of Lumbar Interbody Fusion: Temporal Changes of Bone Turnover Markers.
Hyakkan R; Kanayama M; Takahata M; Oha F; Hashimoto T; Iwasaki N
Spine (Phila Pa 1976); 2021 Dec; 46(23):1645-1652. PubMed ID: 33882539
[TBL] [Abstract][Full Text] [Related]
17. Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis.
Chao TY; Wu YY; Janckila AJ
Clin Chim Acta; 2010 Nov; 411(21-22):1553-64. PubMed ID: 20599857
[TBL] [Abstract][Full Text] [Related]
18. Correlation of Osteoporosis in Patients With Newly Diagnosed Type 2 Diabetes: A Retrospective Study in Chinese Population.
Wen Y; Li H; Zhang X; Liu P; Ma J; Zhang L; Zhang K; Song L
Front Endocrinol (Lausanne); 2021; 12():531904. PubMed ID: 34054717
[TBL] [Abstract][Full Text] [Related]
19. High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.
Ishikawa K; Nagai T; Sakamoto K; Ohara K; Eguro T; Ito H; Toyoshima Y; Kokaze A; Toyone T; Inagaki K
Ther Clin Risk Manag; 2016; 12():1831-1840. PubMed ID: 27980413
[TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of serum bone metabolic markers in diagnosis and monitoring of myeloma bone disease].
Peng F; Fu R; Liu H; Wang Y; Ding K; Ding S; Liu Z; Ruan E; Qu W; Wang H; Xing L; Wang X; Wang G; Song J; Wu Y; Li L; Liu H; Guan J; Shao Z
Zhonghua Yi Xue Za Zhi; 2015 Nov; 95(42):3436-9. PubMed ID: 26813134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
